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Abstract
Objective. Vascular changes are observed in most cases of Alzheimer’s disease (AD). Observations of AD and vascular 
disease (VD) allow us to surmise that vascular changes may not only affect cognitive impairment in AD but may also have a 
negative influence on the neuropsychiatric symptoms which often occur in the course of the disease. The aim of the study 
was to evaluate the impact of vascular factors on the neuropsychiatric symptoms in Alzheimer’s Disease.   
Material and methods. The study included 48 people with a preliminary diagnosis of Alzheimer’s Disease on the basis of 
NINCDS/ADRDA criteria. The evaluation of impairments in cognitive functioning was carried out by means of the Alzheimer 
Disease Assessment Scale – the cognitive part (ADAS – cog), whereas the behavioural and psychological symptoms were 
evaluated by means of the Neuropsychiatric Inventory – the version adapted for residents of nursing homes for the elderly 
(Neuropsychiatric Inventory – Nursing Home Version) (NPI – NH). The score on the Hachinski scale was the basis for dividing 
the study participants into two groups – those with a mild vascular component (0–1 points on the Hachinski scale) and 
those with a severe vascular component (2–4 points).   
Results. The analyzed groups did not differ with respect to the intensity of cognitive impairments (ADAS-cog) or age of 
the participants. Scores obtained on the NPI – NH scale as well as some of its elements (depression/dysphoria and anxiety) 
had a discriminating value.   
Studies show that vascular factors are a serious risk factor for neuropsychiatric symptoms in AD.   
Conclusions. Vascular factors in Alzheimer’s Disease influence the presence of neuropsychiatric symptoms. In the course 
of angiogenic dementia a greater frequency in depressive disorders was shown. The most visible differences between 
individuals with a greater and lesser burden of vascular factors was in the realm of depressive and dysphoric disorders.
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INTRODUCTION
Typical changes within Alzheimer’s as a disease involve 
the degeneration of nerve cells, this most often occurring 
in the structures of the hippocampus and olfactory cortex, 
and subsequently spreading to the frontal, temporal, and 
parietal associative cortex [1]. There also simultaneously 
occurs in Alzheimer’s varied vascular changes which have 
been noted in around a third of patients with Alzheimer’s 
[2]. Additionallyy, some of the vascular changes (amyloid 
angiopathy, pericellular leucoencephalopy) are seen in almost 
all tested cases of Alzheimer’s [3].
Between the dementias of Alzheimer’s and angiogenic 
dementias there exist certain differences within the clinical 
picture. Patients with angiogenic dementias often display 
greater difficulties in the course of function evaluation 
connected with localised mechanisms in the frontal lobes 
and the subcortical areas. However, patients with Alzheimer’s 
usually present a more intensified disturbance in the course 
of undertaking tests for the evaluation of memory and 
linguistic functions [4].
Besides the distinctness in relation to disturbances to the 
cognitive symptoms, there is equally observed a difference 
within the neuropsychiatric symptoms. Under this notion, 
after Cummings, there should be understood a series of 
psychopathological symptoms not directly connected with 
the cognitive sphere, such as mood disturbance, anxiety, 
stimulation (arousal) psychotic symptoms, sleep disturbance, 
and a series of others [5]. Data exist showing the varied 
intensification of such symptoms depending on the presence 
of a vascular substratum [6].
In tests carried out earlier based on a patient population 
of outpatients, the influence of vascular factors on the 
psychopathological image of Alzheimer’s was noted [7]. The 
presented research was conducted upon a more uniform 
patient population, as well as being based, in comparison 
to earlier tests conducted, on widely accepted and more 
appropriate methods for the measurement of neuropsychiatric 
symptoms.
OBJECTIVE
The aim of the research was evaluation of the influence of 
vascular factors present within Alzheimer’s on the frequency 
in the appearance and intensification of neuropsychiatric 
symptoms.
Address for correspondence:  Mariola Bidzan, Institute of Psychology, University 
of Gdansk, Bazynskiego 4, 80-952 Gdansk, Poland
e-mail: mariola.bidzan@ug.edu.pl
Received: 10 August 2013; accepted: 3 September 2013  
       -               -               -               -               -       Annals of Agricultural and Environmental Medicine 2014, Vol 21, No 2
Mariola Bidzan, Leszek Bidzan, Maria Pachalska. Neuropsychiatric symptoms in patients with Alzheimer’s disease with a vascular component
MATERIALS AND METHOD
The initial population were individuals residing at a 
Social Care Home in Gdynia (n = 188). Patients with 
diagnosed Alzheimer’s were qualified for the research. 
The initial procedure for inclusion in the research was the 
obtainment of permission for participation in the tests, 
as well as an evaluation of the criteria excluding testing 
i.e., the presence at the moment of testing or during the 
course of the questionnaire of one of the following diseases: 
affective disease, schizophrenia, alcoholism, addiction to 
medications or intoxicants, epilepsy, Parkinson’s disease, 
mental handicaps; the presence at the moment of testing 
of disturbances in consciousness, lower limb, eye or 
hearing conditions noticeably hampering the carrying out 
instructions and procedures contained within the applied 
clinical scales, and serious somatic ailments. The initial 
selection also incorporated the use of the MMSE scale [8]. 
Verification in the diagnosis of AD was carried out for all of 
those tested who in the test using the MMSE scale obtained 24 
or fewer points. The diagnostic approach in the confirmation 
or exclusion of probable Alzheimer’s was based on NINCDS/
ADRDA criteria [9]. In all of those tested, the Hachinski 
scale was applied. [10]. As a criterion for exclusion was the 
adoption of a Hachinski Scale score of more than 4 points.
Evaluation of the cognitive functions of patients 
included into the research was conducted on the basis of 
the Alzheimer’s Disease Assessment Scale (ADAS) [11]. An 
11-element subscale (ADAS – cog) for the evaluation of 
cognitive functions was used in the tests (speech quality, 
understanding of spoken language, remembering test 
instructions, difficulty with finding the right words during 
spontaneous speech, understanding instructions, naming of 
objects and fingers of the hand, copying figures/diagrams, 
ideomotor activities, orientation, remembering words, 
word recognition). The result of the cognitive part is placed 
within the range 0–70 points, where 0 means an absence 
of any difficulty whatsoever, while 70 means deep-rooted 
dementia.
The frequency of the appearance and intensification of 
neuropsychiatric symptoms was evaluated on the basis of 
the Neuropsychiatric Inventory, the version for nursing 
homes (NPI) developed by Cummings et al. [12, 13]. The 
Neuropsychiatric Inventory in the version employed in the 
presented research contains an evaluation of 12 categories 
(Tab. 3). For each of the categories, an evaluation is taken in 
relation to the frequency on a four-point scale (1 – sporadic, 
4 – very often) and the depth (intensity) of the disturbances 
on a three-point scale (1 – mild, 3 – deep). Some versions of 
the scale also contain an evaluation of the influence of the 
ascertained disturbances upon the surroundings (annoyance 
factor), which was not analysed in the presented tests. In the 
evaluation of reliability and accuracy NPI obtained high 
scores [13]. A Polish-language version of the NPI-NH scale 
was used in the research. In the evaluation of the reliability 
of the Polish-language version the following results were 
obtained: evaluation of internal conformity: 0.92; evaluation 
of retesting reliability (test retest reliability): 0.69; evaluation 
of comparability (interrater reliability): 0.85 [14]. In addition 
the Montgomery-Asberg Depression Rating Scale (MADRS) 
was introduced [15].
The testing by means of the MADRS and NPI -NH scales 
was conducted exclusively by a specialist psychiatrist. The 
ADAS-cog scale was applied also by a specialist psychiatrist 
or clinical psychologist. However, social workers and nursing 
staff independently applied the MMSE, as well as constituting 
the source of information in conducting the NPI-NH scale.
In the presented study, 48 persons with diagnosed 
Alzheimer’s were tested who had an average age of 70. The 
Hachinski scale result constituted the basis for differentiating 
the two test groups. The result that fitted the 0–1 point band 
resulted in the patients being placed in the group with an 
insignificant burdening with vascular factors – this condition 
was fulfilled by 22 people, while those with a result of 2–4 
points were qualified as being burdened with a significant 
vascular factor, which applied to 26 individuals.
Analysis of the statistics was based on a test conducted 
for two mean independents, for which the average values of 
the applied clinical scales between the analysed groups were 
compared. The adopted level of significance (p) was 0.05. 
The results of the tests for which the level of significance was 
equal or lower than 0.05 (p<0.05 or p=0.05) was considered 
significant, while the remaining (p>0.05) as non-significant 
in the adoption of a two-sided division.
RESULTS
Table 1 are presented the mean values for age as well as the 
results of tests using the ADAS-cog, the MADRS scale and 
the NIP – NH scale.
In Table 2 are compared the mean values of age as well as 
the applied scales obtained for individuals with a low value 
on the Hachinski scale (0–1 points) and a high value (2–4 
points). Neither group differentiated in terms of age nor 
intensification of disturbances to the cognitive functions 
(ADAS-cog), while individuals with a high Hachinski 
Scale result also obtained a higher score on the MADRS 
scale; however, this dependence did not obtain statistical 
confirmation. Depressive and dysphoric disorders according 
to the NPI –NH scale, as well as an intensification in anxiety, 
were different in both groups. Equally, the differences in 
the total evaluation of disinhibition were close to statistical 
significance. In each of the discussed variables, a greater 
intensification in psychopathological phenomena occurred 
in individuals with a greater degree of burdening by potential 
vascular factors. Also in this group, a higher combined result 
of the NIP-NH scale was characteristic.
Table 1.  Mean results of age and values obtained in scales applied for 
the tested population (n = 48). 
Variable mean Min Max SD
age 70.00 52.00 85.00  8.02
MMSE  15.96  0.00 24.00  4.91
Hachinski  1.77  0.00  5.00  1.37
ADAS – cog 32.14 14.66 69.00 12.45
MADRS 11.23  0.00 35.00  7.97
NPI 28.83  3.00 56.00 12.18
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DISCUSSION
The vascular factors that widely occur in Alzheimer’s 
are treated as an increase in the risk of the disease. The 
observations of patients with angiogenic dementia and 
Alzheimer’s show a certain changeability in the area of 
neuropsychiatric symptom manifestation. Also, the presence 
of vascular factors within the conducted tests significantly 
influences the psychopathological image of individuals with 
diagnosed Alzheimer’s disease. However, no noticeable 
differences were noted with regard to the very intensification 
of the dementia process evaluated by the ADAS-cog scale; 
differences concerned first and foremost extra-cognitive 
symptoms appearing during the course of dementia. The 
clearest differences between those with a higher and lower 
burdening by vascular factors concerned depressive and 
dysphoric disorders. The results obtained show concurrence 
with those tests in which a greater frequency in depressive 
disorders during the course of angiogenic dementia was 
displayed [16]. Here, it is worth drawing attention to a 
range of publications pointing to a certain specific type 
of depression, referred to as vascular depression which is 
connected with advanced years and the presence in the MRI 
image of hyper-intensive zones of an ischaemic character, 
particularly in white matter and in the pericellular regions 
[17]. Regardless of the numerous controversies connected 
with the notion of vascular depression, it follows that the 
postulated connection of a lowered mood (state of mind) with 
the presence of vascular factors should be pointed out [18].
Almost all the participants in the tests conducted 
underwent neuroimaging tests; however, in the majority of 
those tested only a computer tomography was carried out. 
Unfortunately, with regard to this, it was therefore impossible 
to conduct an appropriate evaluation of the appearance of 
ischaemic focuses in the patients. Indirectly, however, one 
may, via the result obtained on the Hachinski Scale, refer to 
an intensification in vascular factors.
Other elements evaluated by the NPI-NH Scale which 
differed within the two groups were anxiety (in relation 
to intensification) and disinhibition; however, statistical 
confirmation was not obtained for the latter. The remaining 
elements of evaluation by means of the NPI–NH Scale also 
appear to show a greater tendency for manifestation in 
individuals with a greater intensification of vascular factors. 
This was confirmed by a statistically documented increased 
intensification in the joint NPI-NH evaluation.
The connection between the vascular factors and the often 
appearance of neuropsychiatric symptoms presumably has 
complex circumstances, and the confirmed differences may 
be explained on the basis of structural tests of the brain. 
An example of this are the above-mentioned changes in the 
MRI tests for individuals with depressive mood disorders.
The neurotransmitter systems of the brain are another area 
contributing important information useful in explaining the 
observed dependences. Certain aspects of research show a 
connection between disturbances in brain transmission and 
the appearance of certain neuropsychiatric symptoms [19]. 
It cannot be excluded that the presence of vascular factors 
additionally hamper the cholinergic transmission, as well 
as the functioning of other systems. [20]. The presence of 
vascular factors in Alzheimer’s is treated by many authors as 
a widespread phenomenon, and they even show the vascular 
process as initiating the very process of the degeneration 
Table 2. Mean results for age, ADAS cog scale, MADRS and NPI - NH 
(individual categories of disorder are presented) in individuals with a 
lower (Hachinski Scale result 0 -1 pts) and higher (Hachinski Scale result 
2 – 4 pts) burdened by vascular factors. 
Variable 
Hachinski 0–1 
n = 22
Hachinski 2–4 pkt 
n = 26 Signifi­
cance  average/ 
mean SD average/ 
mean  SD
Age 69.48 8.10 70.42 8.11 NS
ADAS – cog  32.38 14.32 31.94 10.90 NS
MADRS 9.36 7.27 12.81 8.33 NS
A.  DELUSION
frequency: 0.32 0.65 0.46 0.58 NS
intensification: 0.32 0.65 0.42 0.70 NS
frequency x intensification  0.32 0.65 0.42 0.70 NS
B. HALLUCINATION
frequency: 0.23 0.43 0.12 0.33 NS
intensification: 0.27 0.55 0.12 0.33 NS
frequency x intensification 0.27 0.55 0.12 0.33 NS
C. AROUSAL / AGGESSION
frequency: 0.73 0.83 0.92 0.93 NS
intensification: 0.73 0.94 1.12 1.14 NS
frequency x intensification 1.18 1.76 2.00 2.55 NS
D. DEPRESSION / DYSPHORIA 
Frequency:  0.14 0.35 1.27 0.87 p< 0.05
Intensification: 0.14 0.35 1.23 0.95 p< 0.05
Frequency x intensification  0.14 0.35 2.15 2.20 p< 0.05
E. ANXIETY
Frequency: 1.05 0.79 1.42 0.86
p< 0.05
Intensification:  1.05 0.84 1.73 1.15
Frequency x intensification  1.68 1.70 3.04 2.66 p< 0.05
F. MOOD UPLIFTING /  EUPHORIA 
Frequency: 0.50 0.67 0.35 0.56 NS
Intensification: 0.50 0.67 0.35 0.69 NS
Frequency x intensification 0.59 0.80 0.42 0.95 NS
G. APATHY/INDIFFERENCE
Frequency: 0.68 0.89 1.00 0.75 NS
Intensification: 0.73 0.98 0.92 0.69 NS
Frequency x intensification  1.27 1.88 1.38 1.42 NS
 H. DISINHIBITION
Frequency: 0.27 0.46 0.62 0.85 NS
Intensification: 0.41 0.73 0.81 1.13 NS
Frequency x intensification  0.41 0.73 1.35 2.10 p = 0.052
IRRITABILITY/EMOTIONAL INSTABILITY
Frequency: 1.00 0.93 1.04 0.82 NS
Intensification: 1.18 1.10 1.31 1.09 NS
Frequency x intensification  2.05 2.48 2.08 2.06 NS
J. ABNORMAL MOTOR FUNCTIONING 
Frequency: 0.27 0.46 0.12 0.33 NS
Intensification: 0.41 0.73 0.15 0.46 NS
Frequency x intensification  0.41 0.73 0.15 0.46 NS
K. SLEEP AND NOCTURAL ACTIVITY DISORDERS 
Frequency: 0.68 0.84 1.08 1.06 NS
Intensification: 0.82 1.05 1.27 1.28 NS
Frequency x intensification  1.32 1.89 2.58 2.98 NS
L. APPETITE AND EATING DISORDERS 
Frequency: 0.09 0.29 0.23 0.43 NS
Intensification: 0.14 0.47 0.27 0.53 NS
Frequency x intensification  0.14 0.47 0.27 0.53 NS
NPI –sum  22.41 12.92 34.27 8.45 NS
414
 
       -               -               -               -               -       Annals of Agricultural and Environmental Medicine 2014, Vol 21, No 2
Mariola Bidzan, Leszek Bidzan, Maria Pachalska. Neuropsychiatric symptoms in patients with Alzheimer’s disease with a vascular component
of a nerve cell [21]. As a mechanism starting the process is 
indicated by the damage to the blood-brain barrier caused 
by a dysfunctioning of the endothelium of the brain’s vessels 
[21, 22]. An increase in the permeability of the brain’s blood 
vessels, resulting in the penetration of proteins, may cause 
activation of immunological processes initiating the process 
of neuron destruction [23, 24].
The presented research was conducted on residents of an 
old people’s home, thanks to which there was a reduction in 
the number of uncontrolled variables, those which are most 
varied when tests are conducted on out-patient populations. 
Evaluation of the frequency that occurred and intensification 
in neuropsychiatric symptoms was based upon the NPI Scale, 
for which the version designated for the testing of individuals 
residing in care institutions was used. This is very important, 
not only for the results obtained, but also for the comfort of 
the patient according to the modern health care principles 
[25, 26]. On the basis of the presented research, it may be state 
that the application of an instrument of sufficient sensitivity 
and specificity enabled obtaining reliable data from the 
research. In tests that were conducted based on a different 
methodology than that applied previously, conformation was 
obtained of the previous observations showing an increase 
in the frequency of neuropsychiatric symptom manifestation 
and intensity in individuals with a greater burden of vascular 
factors.
Evaluation of the appearance of vascular factors was based 
on the result obtained through the Hachinski Scale which, 
however, constitutes a notable limitation in that it allows 
for wide-ranging conclusions to be drawn. Verification 
of the clinical evaluation for the appearance of vascular 
factors with radiological imaging is essential. Admittedly, 
in some of those tested (n = 16) nuclear magnetic resonance 
was conducted; however, the number in this group made 
it impossible to conduct a reliable evaluation. All the more 
so, that in radiological imaging there needs to be taken 
into consideration not only the quantity and scope of the 
ascertained vascular changes but first and foremost their 
location.
In summing up, it follows that it may be stated that the 
results obtained confirm earlier observations concerning 
the link between vascular changes and the manifestation of 
neuropsychiatric symptoms; however, to allow for a better 
understanding of the matter it is essential that radiological 
verification of the clinical data evaluated by means of the 
Hachinski ischaemic scale should be conducted.
CONCLUSIONS
Vascular factors in Alsheimer’s disease influence the presence 
of neuropsychiatric symptoms. In the course of angiogenic 
dementia a greater frequency in depressive disorders was 
shown. The most visible differences between individuals 
with a greater and lesser burden of vascular factors was in 
the realm of depressive and dysphoric disorders.
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